Repligen | RGEN - PE价格收益



金融业
股票价格
USD
资产
USD 2.95B
现金及等价物
USD 606.78M
销售成本
USD 94.09M
流动资产
USD 1.2B
流动负债
USD 132.66M
债务
USD 690.94M
EBIT
USD 21.13M
EBITDA
USD 43.77M
员工
1.78K
EPS每股收益
USD 0.54
股本和储备
USD 2.11B
销售毛利
USD 110.04M
债务利息支出
USD 5.66M
利息收入
USD 7.31M
贷款资金
USD 551.05M
市值
USD 9.28B
净收入
USD 5.01M
营业费用
USD 183M
营业利润
USD 21.13M
普通股股本
USD 56.43M
PE价格收益
105.09
税前利润
USD 14.15M
销售收入
USD 204M
销售和管理费用
USD 76.62M
股票
USD 186.6M
贸易债权人
USD 33.23M
应收帐款人
USD 157.71M


Pe 更改 日
Agilent 20.53 4.51 2026-03
Align Technology 21.8 0.98 2026-06
Bio Techne 38.75 81.27 2026-03
BioMarin Pharmaceutical 21.07 5.79 2026-06
Bristol-Myers Squibb 16.14 7.06 2026-06
Bruker 46.54 9.74 2026-06
Charles River Laboratories 58.27 29 2026-06
Danaher 32.68 3.4 2026-06
Dentsply International 20.31 9.68 2026-03
General Electric Aerospace 43.09 8.82 2026-06
Henry Schein 19.14 2.25 2026-06
Illumina 48.98 16.53 2026-06
IQVIA Holdings 21.45 2.08 2026-06
Mettler Toledo International 27.29 0.04 2026-06
OraSure Technologies 24.42 12.6 2024-09
Pfizer 11.48 2.16 2026-06
Repligen 105.09 4.39 2026-06
Revvity 36.47 5.68 2026-06
Thermo Fisher Scientific 26.4 1.31 2026-06
Waters 66.69 36.94 2026-06
West Pharmaceutical Services 42.63 10.64 2026-06